QUIDELORTHO CORP Research and Development Expense
QUIDELORTHO CORP (QDEL) reported Research and Development Expense of $48.70 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- QUIDELORTHO CORP research and development expense for the quarter ending 2026-06-28 was $48.70M, a 6.56% increase year-over-year.
- QUIDELORTHO CORP research and development expense for the quarter ending 2026-03-29 was $44.90M, a 15.60% decline year-over-year.
- QUIDELORTHO CORP research and development expense for the quarter ending 2025-12-28 was $45.80M, a 3.17% decline year-over-year.
- QUIDELORTHO CORP research and development expense for the quarter ending 2025-09-28 was $41.50M, a 25.76% decline year-over-year.
- QUIDELORTHO CORP research and development expense for fiscal 2025 was $186.20M, a 14.86% decline from fiscal 2024.
- QUIDELORTHO CORP research and development expense for fiscal 2024 was $218.70M, a 10.73% decline from fiscal 2023.
- QUIDELORTHO CORP research and development expense for fiscal 2023 was $245.00M, a 30.39% increase from fiscal 2023.
- QUIDELORTHO CORP research and development expense for fiscal 2023 was $187.90M, a 96.34% increase from fiscal 2022.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | $48.70M 10-Q · filed 2026-08-07 | $93.60M 10-Q · filed 2026-08-07 | $139.40M derived: sum of 3 quarters · filed 2026-08-07 | $180.90M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-29 | $44.90M 10-Q · filed 2026-05-06 | $90.70M derived: sum of 2 quarters · filed 2026-05-06 | $132.20M derived: sum of 3 quarters · filed 2026-05-06 | $177.90M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-28 | $45.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $87.30M derived: sum of 2 quarters · filed 2026-02-19 | $133.00M derived: sum of 3 quarters · filed 2026-08-07 | $186.20M 10-K · filed 2026-02-19 | ||||
| 2025-09-28 | $41.50M 10-Q · filed 2025-11-06 | $87.20M derived: sum of 2 quarters · filed 2026-08-07 | $140.40M 10-Q · filed 2025-11-06 | $187.70M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-29 | $45.70M 10-Q · filed 2026-08-07 | $98.90M 10-Q · filed 2026-08-07 | $146.20M derived: sum of 3 quarters · filed 2026-08-07 | $202.10M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-30 | $53.20M 10-Q · filed 2026-05-06 | $100.50M derived: sum of 2 quarters · filed 2026-05-06 | $156.40M derived: sum of 3 quarters · filed 2026-05-06 | $212.70M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-29 | $47.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $103.20M derived: sum of 2 quarters · filed 2026-02-19 | $159.50M derived: sum of 3 quarters · filed 2026-02-19 | $218.70M 10-K · filed 2026-02-19 | ||||
| 2024-09-29 | $55.90M 10-Q · filed 2025-11-06 | $112.20M derived: sum of 2 quarters · filed 2025-11-06 | $171.40M 10-Q · filed 2025-11-06 | $230.70M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-06-30 | $56.30M 10-Q · filed 2025-08-06 | $115.50M 10-Q · filed 2025-08-06 | $174.80M derived: sum of 3 quarters · filed 2026-02-19 | $236.30M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-03-31 | $59.20M 10-Q · filed 2025-05-08 | $118.50M derived: sum of 2 quarters · filed 2026-02-19 | $180.00M derived: sum of 3 quarters · filed 2026-02-19 | $242.40M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2023-12-31 | $59.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $120.80M derived: sum of 2 quarters · filed 2026-02-19 | $183.20M derived: sum of 3 quarters · filed 2026-02-19 | $245.00M 10-K · filed 2026-02-19 | $246.80M 10-K · filed 2024-02-29 | |||
| 2023-10-01 | $61.50M 10-Q · filed 2024-11-08 | $62.40M 10-Q · filed 2023-11-02 | $123.90M derived: sum of 2 quarters · filed 2024-11-08 | $185.70M 10-Q · filed 2024-11-08 | $187.50M 10-Q · filed 2023-11-02 | $247.90M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-07-02 | $62.40M 10-Q · filed 2024-08-01 | $62.80M 10-Q · filed 2023-08-09 | $124.20M 10-Q · filed 2024-08-01 | $125.10M 10-Q · filed 2023-08-09 | $186.40M derived: sum of 3 quarters · filed 2025-02-27 | $252.00M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-04-02 | $62.30M 10-Q · filed 2024-05-09 | $124.00M derived: sum of 2 quarters · filed 2025-02-27 | $189.60M derived: sum of 3 quarters · filed 2025-02-27 | $223.80M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-01-01 | $61.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $127.30M derived: sum of 2 quarters · filed 2025-02-27 | $161.50M derived: sum of 3 quarters · filed 2025-02-27 | $187.90M 10-K · filed 2025-02-27 | $190.50M 10-K · filed 2023-02-23 | |||
| 2022-10-02 | $65.60M 10-Q · filed 2023-11-02 | $99.80M derived: sum of 2 quarters · filed 2023-11-02 | $126.20M 10-Q · filed 2023-11-02 | $152.30M derived: sum of 4 quarters · filed 2024-08-01 | ||||
| 2022-07-03 | $34.20M 10-Q · filed 2023-08-09 | $60.60M 10-Q · filed 2023-08-09 | $86.70M derived: sum of 3 quarters · filed 2024-08-01 | $110.40M derived: sum of 4 quarters · filed 2024-08-01 | ||||
| 2022-04-03 | $26.40M 10-Q · filed 2023-05-04 | $52.50M derived: sum of 2 quarters · filed 2024-08-01 | $76.20M derived: sum of 3 quarters · filed 2024-08-01 | $98.80M derived: sum of 4 quarters · filed 2024-08-01 | ||||
| 2022-01-02 | $26.10M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-08-01 | $49.80M derived: sum of 2 quarters · filed 2024-08-01 | $72.40M derived: sum of 3 quarters · filed 2024-08-01 | $95.70M 10-K/A · filed 2024-08-01 | ||||
| 2021-10-03 | $23.70M 10-Q · filed 2022-11-04 | $46.30M derived: sum of 2 quarters · filed 2022-11-04 | $69.60M 10-Q · filed 2022-11-04 | |||||
| 2021-07-04 | $22.60M 10-Q · filed 2022-08-05 | $45.90M 10-Q · filed 2022-08-05 | ||||||
| 2021-01-03 | $84.30M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |